Research progress on resistance mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer

Chinese Journal of Lung Cancer

Volumn 15, Issue 2, 2012, Pages 106-111

  Li, Yuan ^a   Song, Lihua ^a  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Drug resistance; Epidermal growth factor receptor tyrosine kinase inhibitors; Lung neoplasms; Mechanism

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB;

CHEMOSENSITIVITY; DRUG EFFICACY; NON SMALL CELL LUNG CANCER; REVIEW; TREATMENT RESPONSE;

EID: 84922686321     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: 10.3779/j.issn.1009-3419.2012.02.08     Document Type: Review

References (35)

1. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med, 2009, 361(10): 958-967.
2. Reply to Watkins and Rukazenkov (J Cell Mol Med 2010), re-Letter of response to manuscript entitled' clinical outcomes in NSCLC patients with EGFR mutations: pooled analysis' (Paz-Ares et al., J Cell Mol Med. 2010; 14(1-2): 51-69). J Cell Mol Med, 2011, 15(5):1225.
3. Sequist LV, Bell DW, Lynch TJ, et al. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol, 2007, 25(5): 587-595.
4. T. Mitsudomi, Y. Yatabe. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Science, 2007, 98(12): 1817-1824.
5. Greulich H, Chen TH, Feng W, et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med, 2005, 2(11): e313.
6. Tam IY, Chung LP, Suen WS, et al. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopa-thologic features. Clin Cancer Res, 2006, 12(5): 1647-1653.
7. Linardou H, Dahabreh IJ, Bafaloukos D, et al. Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nat Rev Clin Oncol, 2009, 6(6): 352-366.
8. Sun L, Zhang Q, Luan HL, et al. Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice. J Experimental Clin Cancer Res, 2011, 30(1): 30.
9. Zhu CQ, da Cunha Santos G, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol, 2008, 26(26): 4268-4275.
10. Sasaki H, Hikosaka Y, Kawano O, et al. Evaluation of Kras gene mutation and copy number gain in non-small cell lung cancer. J Thorac Oncol, 2011, 6(1): 15-20.
11. Poulikakos PI, Zhang C, Bollag G, et al. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature, 2010, 464(7287): 427-430.
12. Pallis A, Briasoulis E, Linardou H, et al. Mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small-cell lung cancer: clinical and molecular considerations. Current Medicinal Chemistry, 2011, 18(11): 1613-1628.
13. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol, 2009, 27(26): 4247-4253.
14. Benedettini E, Sholl LM, Peyton M, et al. Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. Am J Pathol, 2010, 177(1): 415-423.
15. Turke AB, Zejnullahu K, Wu YL, et al. Pre-existence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell, 2010, 17(1): 77-88.
16. Jackman D, Pao W, Riely GJ, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-smallcell lung cancer. J Clin Oncol, 2010, 28(2): 357-360.
17. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med, 2005, 352(8): 786-792.
18. Yun CH, Mengwasser KE, Toms AV, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA, 2008, 105(6): 2070-2075.
19. Inukai M, Toyooka S, Ito S, et al. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res, 2006, 66(16): 7854-7858.
20. Maheswaran S, Sequist LV, Nagrath S, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med, 2008, 359(4): 366-377.
21. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science, 2007, 316(5827): 1039-1043.
22. Schiller JH, Akerley WL, Brugg er W, et al. Results from ARQ 197-209: A global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitornaive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol, 2010, 28: LBA7502.
23. Witta SE, Gemmill RM, Hirsch FR, et al. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res, 2006, 66(2): 944-950.
24. Yauch RL, Januario T, Eberhard DA, et al. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancerpatients. Clin Cancer Res, 2005, 11(24 Pt1): 8686-8698.
25. Miyanaga A, Gemma A, Ando M, et al. E-cadherin expression and epidermal growth factor receptor mutation status predict outcome in non-small cell lung cancer patients treated with gefitinib. Oncol Rep, 2008,19(2): 377-383.
26. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol, 2010, 11(2): 121-128.
27. Morgillo F, Kim WY, Kim ES, et al. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res, 2007, 13(9): 2795-2803.
28. Guix M, Faber AC, Wang SE, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest, 2008, 118(7): 2609-2619.
29. Ios ML, Koker M, Weir BA, et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res, 2009, 69(8): 3256-3261.
30. Kjm SM, Kim JS, Kim JH, et al. Acquired resistance to cetuximab is mediated by increased PTEN instability and leads cross-resistance to gefitinib in HCC827 NSCLC cells. Cancer Lett, 2010, 296(2): 150-159.
31. Vivanco I, Rohle D, Versele M, et al. The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation. Proc Natl Acad Sci USA, 2010, 107(14): 6459-6464.
32. Yao Z, Fenoglio S, Gao DC, et al. TGF-{beta} IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc Natl Acad Sci USA, 2010, 107(35): 15535-15540.
33. Ware KE, Marshall ME, Heasley LR, et al. Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression. PLoS One, 2010, 5(11): e14117.
34. Chen YJ, Huang WC, Wei YL, et al. Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells. PLoS One, 2011, 6(6): e21428.
35. Oxnard GR, Arcila ME, Chmielecki J, et al. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res, 2011, 17(17): 5530-5537.